Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A qualitative study exploring access to online hearing loss information and support for adults with hearing loss.

Frontiers in digital health·2026

Same author

Helical classification of type B aortic dissections.

JTCVS structural and endovascular·2026

Same author

Three-year outcomes of endovascular repair of descending thoracic aortic lesions with a single-branched endograft for left subclavian artery preservation.

JTCVS structural and endovascular·2026

Same author

Machine Learning Approach for Enumeration of Circulating Cells with Diffuse <i>in vivo</i> Flow Cytometry.

bioRxiv : the preprint server for biology·2026

Same author

Major Adverse Limb Events and Death After Successful Endovascular Revascularization: BEST-CLI Trial.

Journal of the Society for Cardiovascular Angiography & Interventions·2026

Same author

Randomised al.Phase 2b trial of rhIGF-1/rhIGFBP-3 (OHB-607) for bronchopulmonary dysplasia prevention in preterm neonates: study protocol.

BMJ paediatrics open·2026

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development.

Jacob M Waugh¹, Jane Lee, Michael D Dake

¹Revance Therapeutics Inc, Newark, CA, USA.

Methods in Molecular Biology (Clifton, N.J.)

|November 6, 2010

Summary

Rational design of cyclodextrin-based nanoparticles (CD-based CPPs) for transcutaneous delivery is explored. This study details how design choices impact nonclinical and clinical outcomes for improved drug delivery systems.

More Related Videos

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Related Experiment Videos

Last Updated: Jun 7, 2026

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Area of Science:

Biomaterials Science
Drug Delivery
Nanotechnology

Background:

Transcutaneous drug delivery offers advantages over traditional routes.
Cyclodextrin-based complexation and peptide (CPP) systems are promising for enhanced skin permeation.
Optimizing these systems requires careful consideration of design parameters.

Purpose of the Study:

To outline key considerations for the rational design of cyclodextrin-based peptide (CPP) transcutaneous delivery systems.
To analyze the influence of specific design elements on nonclinical and clinical performance.

Main Methods:

Literature review and synthesis of existing research on CPP-based transcutaneous systems.
Analysis of structure-property relationships in CPP formulation design.
Evaluation of preclinical and clinical data correlating design features with efficacy and safety.

Main Results:

Specific CPP modifications and cyclodextrin complexation strategies significantly affect skin penetration and bioavailability.
Formulation parameters, including particle size and charge, correlate with nonclinical efficacy and safety profiles.
Clinical outcomes demonstrate a direct link between rational design choices and therapeutic success.

Conclusions:

Rational design is critical for developing effective and safe CPP-based transcutaneous drug delivery systems.
Understanding the impact of design considerations on both nonclinical and clinical results is essential for successful translation.
Further research should focus on optimizing CPP-CD interactions for targeted and efficient transdermal therapies.